ReviewNaunyn-Schmiedeberg's archives of pharmacology2026
The effect of CD40 agonist antibody therapy on the pancreatic cancer microenvironment.
Review in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The fourth leading cause of cancer-related fatalities in the USA is pancreatic ductal adenocarcinoma (PDAC), a particularly deadly illness that is resistant to immunotherapy. One of the Main Obstacles in cancer research is developing better treatments for PDAC, which has the lowest 5-year survival rate of any malignancy. Anti-CTLA-4, anti-PD-L1, and anti-PD-1 immune checkpoint blockade medications also have poor results in these patients, which may indicate the presence of other immunosuppressive mechanisms in the pancreatic tumor microenvironment (TME). A new therapeutic avenue for cancer immunotherapy is CD40 activation. When CD40 is activated, it can retrain macrophages to eliminate tumor stroma and license dendritic cells to encourage anticancer T-cell activation. Several different formulations of agonist CD40 antibodies have been tested in clinical settings and determined to be both viable and tolerated. A number of agonistic CD40 monoclonal antibody (mAb) clinical trials are now underway, but little is known about the biological consequences and treatment-related regulation of the TME. Because CD40 agonist antibodies (αCD40) improve macrophage tumoricidal activity and promote antigen-presenting cell (APC) development, they may change the pancreatic TME to make it more susceptible to immune checkpoint blockage. It is believed that CD40 agonists work through T-cells and macrophages to provide antitumor effects on PDAC. Rapid tumor infiltration, tumoricidal effects, and tumor stroma depletion were all boosted by CD40-activated macrophages. Therefore, this study provides a CD40-dependent strategy for targeting tumor stroma in cancer treatment, indicating that cancer immune surveillance does not necessarily rely on therapy-induced T-cells. The purpose of this study was to examine how CD40 agonist antibody therapy might change the microenvironment and treat PDAC in humans.
Indexed as
Identifiers
40928654What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.